Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Haemophilia"
DOI: 10.1111/hae.13191
Abstract: Nonacog beta pegol (N9‐GP) is a glycoPEGylated recombinant factor IX (FIX) with an extended half‐life developed for routine prophylaxis and the prevention and treatment of bleeding episodes in patients with haemophilia B. read more here.
Keywords: extended half; patients haemophilia; beta pegol; nonacog beta ... See more keywords